Sutro Biopharma Inc. [NASDAQ: STRO] jumped around 5.65 points on Friday, while shares priced at $22.65 at the close of the session, up 33.24%. The company report on December 4, 2020 that Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer.
– Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose levels-including 1 CR, 3 cPRs and 6 uPRs -.
– Disease control rate at 12 weeks is 74% (23/31) and 10 patients remained on treatment -.
Sutro Biopharma Inc. stock is now 105.91% up from its year-to-date (YTD) trading value. STRO Stock saw the intraday high of $25.49 and lowest of $21.80 per share. The company’s 52-week high price is 19.18, which means current price is +277.50% above from all time high which was touched on 12/04/20.
Compared to the average trading volume of 370.90K shares, STRO reached a trading volume of 4611924 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sutro Biopharma Inc. [STRO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for STRO shares is $21.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on STRO stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Sutro Biopharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 03, 2020. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 02, 2020, representing the official price target for Sutro Biopharma Inc. stock. Previously, the target price had yet another raise to $18, while Wells Fargo analysts kept a Overweight rating on STRO stock.
The Average True Range (ATR) for Sutro Biopharma Inc. is set at 1.66, with the Price to Sales ratio for STRO stock in the period of the last 12 months amounting to 14.36. The Price to Book ratio for the last quarter was 3.42, with the Price to Cash per share for the same quarter was set at 9.71.
How has STRO stock performed recently?
Sutro Biopharma Inc. [STRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.46. With this latest performance, STRO shares gained by 62.72% in over the last four-week period, additionally plugging by 127.87% over the last 6 months – not to mention a rise of 126.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for STRO stock in for the last two-week period is set at 77.29, with the RSI for the last a single of trading hit 80.49, and the three-weeks RSI is set at 74.74 for Sutro Biopharma Inc. [STRO]. The present Moving Average for the last 50 days of trading for this stock 14.06, while it was recorded at 17.98 for the last single week of trading, and 10.60 for the last 200 days.
Sutro Biopharma Inc. [STRO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sutro Biopharma Inc. [STRO] shares currently have an operating margin of -129.79. Sutro Biopharma Inc.’s Net Margin is presently recorded at -130.44.
Return on Total Capital for STRO is now -43.69, given the latest momentum, and Return on Invested Capital for the company is -44.92. Return on Equity for this stock declined to -48.62, with Return on Assets sitting at -29.38. When it comes to the capital structure of this company, Sutro Biopharma Inc. [STRO] has a Total Debt to Total Equity ratio set at 10.10. Additionally, STRO Total Debt to Total Capital is recorded at 9.17, with Total Debt to Total Assets ending up at 6.32. Long-Term Debt to Equity for the company is recorded at 9.08, with the Long-Term Debt to Total Capital now at 8.24.
Reflecting on the efficiency of the workforce at the company, Sutro Biopharma Inc. [STRO] managed to generate an average of -$331,810 per employee. Receivables Turnover for the company is 9.73 with a Total Asset Turnover recorded at a value of 0.23.Sutro Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.80 and a Current Ratio set at 9.80.
Earnings analysis for Sutro Biopharma Inc. [STRO]
With the latest financial reports released by the company, Sutro Biopharma Inc. posted -0.64/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for STRO.
Insider trade positions for Sutro Biopharma Inc. [STRO]
There are presently around $701 million, or 98.20% of STRO stock, in the hands of institutional investors. The top three institutional holders of STRO stocks are: ECOR1 CAPITAL, LLC with ownership of 3,113,617, which is approximately 70.283% of the company’s market cap and around 0.70% of the total institutional ownership; BVF INC/IL, holding 3,087,195 shares of the stock with an approximate value of $69.92 million in STRO stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $47.98 million in STRO stock with ownership of nearly 10.344% of the company’s market capitalization.
Positions in Sutro Biopharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 57 institutional holders increased their position in Sutro Biopharma Inc. [NASDAQ:STRO] by around 7,501,526 shares. Additionally, 28 investors decreased positions by around 1,088,368 shares, while 13 investors held positions by with 22,340,448 shares. The mentioned changes placed institutional holdings at 30,930,342 shares, according to the latest SEC report filing. STRO stock had 18 new institutional investments in for a total of 1,904,945 shares, while 10 institutional investors sold positions of 757,686 shares during the same period.